Trial Profile

Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2024 Results assessing safety of Tenofovir Alafenamide over 5 years presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
14 Sep 2021 Results(n=31) assessing Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate published in the JAIDS
10 Mar 2021 Results (n=31) assessing safety of tenofovir alafenamide with a history of Proximal Renal Tubulopathy while receiving TDF, presented at the 28th Conference on Retroviruses and Opportunistic Infections

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com